Modra Pharmaceuticals
Colin Freund is a Partner at Delin Ventures since October 2023. Previously, Colin served as the CEO at Modra Pharmaceuticals since September 2017. Currently, Colin also holds a position as a Board Member at Citryll B.V. Advising QUE Oncology during the company's transition to Australia from September 2015 to July 2017, Colin has a wealth of experience in the biotechnology industry. With a background in business development and corporate strategy, Colin has successfully led companies in developing novel therapies for cancer patients and raising venture financing. A graduate of Stanford University Graduate School of Business, Colin has a strong educational foundation in economics and management studies from the University of Cambridge.
This person is not in any teams
This person is not in any offices
Modra Pharmaceuticals
Modra (Modulated Oral Drug Absorption) Pharmaceuticals B.V. is a spin-out from two internationally acclaimed centers of excellence in oncology, the ‘Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)’ and the MC Slotervaart (Slotervaart) in Amsterdam. Modra Pharmaceuticals is a clinical stage company that develops new treatment paradigms by enabling oral bioavailability of existing anticancer drugs, “the iv to oral switch”, to improve cancer therapy and supportive care. Modra Pharmaceuticals has several products in preclinical and clinical development including oral formulations of docetaxel and paclitaxel.